Mark H.H. Kramer

9.3k citations
163 papers · 7.1k · 2 hit papers · h-index 46

Impact in

Papers in

Mark H.H. Kramer

163 papers receiving 6.9k citations

Mark H.H. Kramer's Hit Papers

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial 2019 · 282 citations
2820+3+6Years since publication100200300

Peers

Mark H.H. Kramer
Comparison fields: 5 of 163
  • Internal Medicine 595
  • Endocrinology, Diabetes and Metabolism 2.1k
  • Applied Microbiology and Biotechnology 193
  • Critical Care and Intensive Care Medicine 238
  • Nephrology 345
Replace Toomas Marandi with:
Toomas Marandi Estonia
Gilmar Reis Canada
Michael Fralick Canada
Paul B.J. Burton United States
Basil S. Lewis Israel
Xavier Rosselló Spain
William G. Herrington United Kingdom
Charles R. Bridges United States
Linda L. Humphrey United States
Zumreta Kušljugić Bosnia and Herzegovina
Mark H.H. Kramer relative to Toomas Marandi Estonia Toomas Marandi's profile →
Citations per field
00.5×5×10×16.8×
Toomas Marandi · 1×
Citations per year

Countries citing papers authored by Mark H.H. Kramer

Since Specialization
Citations

This map shows the geographic impact of Mark H.H. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H.H. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H.H. Kramer more than expected).

Fields of papers citing papers by Mark H.H. Kramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H.H. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H.H. Kramer. The network helps show where Mark H.H. Kramer may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark H.H. Kramer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark H.H. Kramer Line = papers co-authored together Mark H.H. Kramer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 163 papers — load more, or switch the sort, to bring in the rest.

#Work
1
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Hit paper breakdown →
2017333
2 2016315
3 2003283
4
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Hit paper breakdown →
2019282
5 2013236
6 2017216
7 2017187
8 2008172
9 2006159
10 2013154
11 2015139
12 2016127
13 2011122
14 2007117
15 2009116
16 2016112
17
Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study.
2013108
18 201692
19 201790
20 200790

About Mark H.H. Kramer

Mark H.H. Kramer is a scholar working on Endocrinology, Diabetes and Metabolism, Internal Medicine, Emergency Medicine, Nephrology and Epidemiology, having authored 163 papers that have together received 7.1k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (33 papers), Venous Thromboembolism Diagnosis and Management (15 papers), Pancreatic function and diabetes (9 papers), Sepsis Diagnosis and Treatment (9 papers), Diabetes Management and Research (8 papers), Emergency and Acute Care Studies (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Kidney Disease and Diabetes (6 papers). The work is most often cited by research in Internal Medicine (595 citations), Endocrinology, Diabetes and Metabolism (2.1k citations), Applied Microbiology and Biotechnology (193 citations), Critical Care and Intensive Care Medicine (238 citations) and Nephrology (345 citations). Mark H.H. Kramer has collaborated with scholars based in Netherlands, United States and Vietnam. Frequent co-authors include Daniël H. van Raalte, Mark M. Smits, Marcel H.A. Muskiet, Lennart Tonneijck, Michaëla Diamant, Prabath W.B. Nanayakkara, Jaap A. Joles, Max Nieuwdorp, Erik H. Serné and Trynke Hoekstra. Their work appears in journals such as Diabetes Obesity and Metabolism, European Journal of Internal Medicine, Diabetes, Diabetic Medicine and Diabetologia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact